The Latest Breaking News from Novo Nordisk

The Dow Jones fell on the stock market today. GameStop surged after influencer "Roaring Kitty" claimed a big stake. AI stock Nvidia popped.

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

As medicines for losing weight become more widely accessed and affordable, people are discussing their experiences.

Amid baby boom reports linked to drugs such as Wegovy and Ozempic, experts say it would be ‘wise’ to take extra precautions

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

Pharmaceutical CEO George Hampton discusses anti-obesity medications and the quickly moving acceleration of their affordability and accessibility.

There's an easy way to lower the cost of next-generation weight-loss drugs.

The company says its Vital Pursuit line, priced under $5, is high in protein and vitamins, addressing nutrient deficiencies that Ozempic and Wegovy users may have.

The compounded weight loss drug starts at $199 per month.

Microsoft is near a buy point with the market rally flashing green. It's one of five stocks to watch.

A recent clinical trial of Wegovy showed that 17 percent of patients on the drug left the trial because of side effects.